Targeted therapy, represented by EGFR antibody drugs, and immunotherapy, represented by anti-PD-1/PD-L1 antibodies, have provided new strategies for the treatment of HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.